Day: January 2, 2025

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

Delota Reports Third Quarter Revenue of $10.3 Million; $29.9 Million for the Nine Months Ended 2025 and Third Consecutive Quarter of Positive Adjusted EBITDA

Highlights:Total revenue of $10.3 million for Q3 2025, reflecting YoY growth of 27% from the comparative quarter37% gross profit margin...

error: Content is protected !!